M.S.D. LIMITED

Discussion health policy that relates to combination therapies, rare diseases including orphan medicines and early access in the Irish healthcare systems

During a site visit to MSD Biotech by political stakeholders MSD raised with members present the importance of the R&D Tax Credit to industry, highlighted the challenges with the current access and reimbursement system in Ireland and discussed the importance of the HPV catch up…

to highlight the need for additional funding and extra resources for the pulmonary arterial hypertension unit in the Mater Hospital to allow it to safely and effectively provide care to patients as newer therapies have become available.

To highlight to the Department of Health research obtained on implementing an early access scheme in Ireland and lessons from European countries

To discuss the need for the reintroduction of a HPV catch-up vaccination programme and to highlight the need for a new methodology of delivery to support increased uptake.

Engagement on behalf of MSD Ireland during a Fingal Chamber of Commerce political stakeholder event where the following matters were discussed: • Mountgorry electrical substation upgrade • R132 road upgrade • Increase housing supply in Dublin • A strong stance on regulatory…

During a site visit to MSD Brinny MSD raised with Oireachtas members present the importance of the R&D Tax Credit to MSD's operations across the country, highlighted the challenges with the current access and reimbursement system in Ireland and discussed the importance of…

To raise awareness of Pulmonary Arterial Hypertension in Ireland and to advocate for health policy change to better support patients with Pulmonary Arterial Hypertension in Ireland.

To highlight to the Minister for Health some of the activities MSD Ireland is undertaking to raise public awareness to help combat HPV related cancer in Ireland and to highlight how MSD Ireland is fully committed to supporting efforts to eliminate cervical cancer in Ireland in…

To highlight the importance during this reform process of ensuring; data confidentiality, restricted access to confidential data on the common data platform, R&D studies are exempt from study notification requirements and that The European Medicines Agency (EMA) remains in the…

To highlight to new office holders the importance of focusing on, Healthcare Innovation, Improving Access to Medicines, the EU Pharmaceutical Legislation Revision (GPL), Public Health Initiatives and the development of a new Life Sciences Strategy in Ireland.

to discuss with Irish European political stakeholders MSD Ireland's position on the current negotiations at the EU Council on the Reform of the EU pharmaceutical legislation (GPL) and the need to ensure that a strong regulatory Data Protection baseline of 8 years remains in…

to highlight to MEP Kelleher how dedicated new medicines funding was not spent on new medicines as anticipated between 2021 and 2023.

To call for a fairer legislative text on the UWWTD which should include other sectors in line with the EU Polluter Pays Principal. ::To request a delay in the signing off on the Directive until a thorough assessment by the legal service of the EU Council is conducted, and an…

To update political stakeholders on the importance of addressing health challenges in Ireland as they relate to access to medicines, oncology services and screening, vaccines, rare diseases and the EU pharmaceutical revision proposals through the provision of the MSD Ireland…